F2RL1 and acute respiratory distress syndrome: In the mouse ARDS model described above, aspiration of SLIGKVNH2, starting 24 h after oropharyngeal aspiration of bleomycin, reduced neutrophil accumulation in lungs at day 3, similar to the effects of DPPIV described above (White et al., 2018), suggesting that aspiration of PAR2 agonists could be used to treat ARDS in human patients (Herlihy et al., 2013; White et al., 2018).